Daewoong Pharmaceutical announced that its botulinum toxin product Nabota has exceeded 1 trillion KRW in cumulative sales this year. To support its expanding global footprint, the company is strengthening the local capabilities of overseas partner firms. Beyond product supply and academic activities for healthcare professionals, Daewoong will directly train partners’ sales, academic and marketing personnel to ensure a consistent brand strategy worldwide.
From the 3rd to the 5th, Daewoong hosted the “NABOTA® EDGE: Global Academic Program” at the Parnas Hotel in Jeju. The event gathered 40 core staff members representing partner companies from 22 countries for intensive training sessions.
The initiative reflects Daewoong’s commitment to building a unified global presence for Nabota as it continues to grow its market share.
Market AnalysisSep 18, 2026•3 min read
Daewoong’s Nabota tops 1 trillion KRW sales, starts global partner training
Daewoong Pharmaceutical’s botulinum toxin Nabota topped 1 trillion KRW in cumulative sales and held a Global Academic Program in Jeju for 40 key staff from partners in 22 countries.
Compiled by the Pharmacountry team · Source: KPA News
Topics:
Ratings
(0)
(0)
(0)
(0)
(0)
Leave your rating